Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Cerebral small vessel disease affects an estimated 700 million people worldwide and accounts for up to 50% of all dementias — yet it's been largely undertreated. Neuroimaging expert Dr. Joanna Wardlaw says the field is finally moving beyond risk factor control, with repurposed cardiovascular drugs showing early promise in slowing cognitive decline and stroke recurrence. A phase 3 trial could deliver real answers within five years.
Cerebral small vessel disease (CSVD) has long flown under the radar despite being one of the most consequential conditions in neurology. It causes about a quarter of all ischemic strokes, most brain hemorrhages in older adults, and contributes to nearly half of all dementias — including worsening Alzheimer's presentations. Dr. Joanna Wardlaw of the University of Edinburgh, speaking at the 2026 World Stroke Congress in Seoul, says the field is finally moving beyond simply managing vascular risk factors like blood pressure and cholesterol.
New research is revealing that CSVD has a deeper biological story: genetic vulnerabilities, leaky and inflamed small blood vessels, and impaired vessel reactivity all play a role. This opens the door to targeted therapies — and some of the most promising candidates are already widely available, inexpensive, generic cardiovascular drugs that may only need a license extension to a brain indication.
By the Numbers:
Why it matters: If even one repurposed drug confirms its early promise, it could rapidly translate into clinical practice — no lengthy drug development pipeline required. That's a potentially game-changing shortcut for a disease affecting hundreds of millions globally.
